BRPI0808764A2 - compostos espiro-substituídos como inibidores de angiogênese - Google Patents

compostos espiro-substituídos como inibidores de angiogênese

Info

Publication number
BRPI0808764A2
BRPI0808764A2 BRPI0808764A BRPI0808764A BRPI0808764A2 BR PI0808764 A2 BRPI0808764 A2 BR PI0808764A2 BR PI0808764 A BRPI0808764 A BR PI0808764A BR PI0808764 A BRPI0808764 A BR PI0808764A BR PI0808764 A2 BRPI0808764 A2 BR PI0808764A2
Authority
BR
Brazil
Prior art keywords
spiro
angiogenesis inhibitors
substituted compounds
substituted
compounds
Prior art date
Application number
BRPI0808764A
Other languages
English (en)
Inventor
Guoqing Paul Chen
Original Assignee
Advenchen Lab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advenchen Lab Llc filed Critical Advenchen Lab Llc
Publication of BRPI0808764A2 publication Critical patent/BRPI0808764A2/pt
Publication of BRPI0808764B1 publication Critical patent/BRPI0808764B1/pt
Publication of BRPI0808764B8 publication Critical patent/BRPI0808764B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0808764A 2007-03-14 2008-02-24 compostos espiro-substituídos como inibidores de angiogênese seu processo de produção e composição farmacêutica BRPI0808764B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US89469307P 2007-03-14 2007-03-14
US60/894,693 2007-03-14
US94169907P 2007-06-04 2007-06-04
US60/941,699 2007-06-04
US12/036,245 US8163923B2 (en) 2007-03-14 2008-02-23 Spiro substituted compounds as angiogenesis inhibitors
US12/036,245 2008-02-23
PCT/US2008/054817 WO2008112408A1 (en) 2007-03-14 2008-02-24 Spiro substituted compounds as angiogenesis inhibitors

Publications (3)

Publication Number Publication Date
BRPI0808764A2 true BRPI0808764A2 (pt) 2015-10-27
BRPI0808764B1 BRPI0808764B1 (pt) 2021-01-12
BRPI0808764B8 BRPI0808764B8 (pt) 2021-05-25

Family

ID=39759894

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808764A BRPI0808764B8 (pt) 2007-03-14 2008-02-24 compostos espiro-substituídos como inibidores de angiogênese seu processo de produção e composição farmacêutica

Country Status (21)

Country Link
US (2) US8163923B2 (pt)
EP (1) EP2125777B1 (pt)
JP (1) JP5441722B2 (pt)
KR (2) KR101540421B1 (pt)
CN (1) CN101558055B (pt)
AU (1) AU2008226667B2 (pt)
BR (1) BRPI0808764B8 (pt)
CA (1) CA2681005C (pt)
CY (1) CY1114092T1 (pt)
DK (1) DK2125777T3 (pt)
ES (1) ES2416711T3 (pt)
HR (1) HRP20130633T1 (pt)
IL (1) IL200854A (pt)
ME (1) ME02323B (pt)
MX (1) MX2009009843A (pt)
NZ (1) NZ579619A (pt)
PL (1) PL2125777T3 (pt)
PT (1) PT2125777E (pt)
RS (1) RS52853B (pt)
SI (1) SI2125777T1 (pt)
WO (1) WO2008112408A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163923B2 (en) * 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
IT1393351B1 (it) 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
KR101940340B1 (ko) 2011-03-04 2019-01-18 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 키나제 억제제로서의 아미노-퀴놀린
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
MA38274A1 (fr) 2013-01-18 2017-02-28 Advenchen Pharmaceuticals Llc Procédé pour l'élaboration d'un agent antitumoral, la 6-(7-((1-amino-cyclo-propyl)-méthoxy)-6- méthoxyquinolin-4-yloxy)-n-méthyl-1-naphthamide, et de sa forme cristalline
BR112015019624A2 (pt) 2013-02-21 2017-07-18 Glaxosmithkline Ip Dev Ltd quinazolinas como inibidores de quinase
FR3009497B1 (fr) * 2013-08-09 2015-08-07 Servier Lab Nouvelle association entre le 6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolein-4-yl}oxy)-n-methylnaphtalene-1-carboxamide et un anti-oestrogene dans le cancer du sein
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
CN105311030B (zh) 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
JP6380777B2 (ja) 2014-07-14 2018-08-29 アドヴェンチェン ファーマスーティカルズ，ナンジン リミテッド ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物
UA122564C2 (uk) 2014-09-26 2020-12-10 Янссен Фармацевтика Нв Використання панелі мутантних генів fgfr для ідентифікації пацієнтів із раковим захворюванням, які піддаються лікуванню інгібітором fgfr
WO2016091168A1 (zh) 2014-12-09 2016-06-16 正大天晴药业集团股份有限公司 抗非小细胞肺癌的喹啉衍生物
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
CN110078730B (zh) 2015-07-11 2021-09-07 南京爱德程医药科技有限公司 作为pi3k/mtor抑制剂的喹啉取代的稠合喹啉化合物
CN106543143B (zh) * 2015-09-22 2019-03-22 合肥中科普瑞昇生物医药科技有限公司 一类新型的flt3激酶抑制剂及其用途
WO2017062500A2 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN107296811B (zh) 2016-04-15 2022-12-30 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物
JOP20190280A1 (ar) 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
CN111936467B (zh) 2018-03-02 2022-02-18 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途
CN110483393A (zh) * 2018-05-14 2019-11-22 上海海和药物研究开发有限公司 德立替尼的晶型
CN110551065B (zh) * 2018-06-01 2021-02-26 海创药业股份有限公司 氘代Lucitanib化合物及其用途
AU2019342289A1 (en) 2018-09-21 2021-03-18 Janssen Pharmaceutica Nv Treatment of cholangiocarcinoma
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CA3130773A1 (en) 2019-03-29 2020-10-08 Peter Marie Z. De Porre Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
WO2020205493A1 (en) 2019-03-29 2020-10-08 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CN112778217B (zh) * 2019-11-08 2024-01-26 沈阳化工研究院有限公司 一种喹唑啉类化合物及其应用
JP2023513704A (ja) 2020-02-12 2023-04-03 ヤンセン ファーマシューティカ エヌ．ベー． 高リスク筋層非浸潤性膀胱癌を治療するためのｆｇｆｒチロシンキナーゼ阻害剤
TWI900527B (zh) 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
AU2021339962A1 (en) 2020-09-14 2023-05-25 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
CN115227675A (zh) * 2021-04-22 2022-10-25 南京爱德程医药科技有限公司 一种含有德立替尼的药物组合物
JP2024518612A (ja) 2021-05-19 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 進行性固形腫瘍の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
AU2023274540A1 (en) 2022-05-24 2024-12-12 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
CN115160221B (zh) * 2022-07-26 2024-10-18 恩祺生物科技(上海)有限公司 德立替尼晶型化合物和用途
CN120500473A (zh) * 2022-12-28 2025-08-15 深圳微芯生物科技股份有限公司 一种萘酰胺类化合物、其制备方法及其应用
CN120813357A (zh) 2023-02-13 2025-10-17 詹森药业有限公司 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003257666A1 (en) * 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
BRPI0416190A (pt) 2003-11-06 2007-01-23 Pfizer Prod Inc combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro
KR100807920B1 (ko) 2003-12-23 2008-02-27 화이자 인코포레이티드 신규한 퀴놀린 유도체
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US8163923B2 (en) * 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors

Also Published As

Publication number Publication date
NZ579619A (en) 2012-03-30
WO2008112408A1 (en) 2008-09-18
KR20150039889A (ko) 2015-04-13
JP5441722B2 (ja) 2014-03-12
ES2416711T3 (es) 2013-08-02
AU2008226667A1 (en) 2008-09-18
BRPI0808764B8 (pt) 2021-05-25
US8513283B2 (en) 2013-08-20
RS52853B (sr) 2013-12-31
EP2125777A1 (en) 2009-12-02
KR20090120483A (ko) 2009-11-24
US20120165371A1 (en) 2012-06-28
CY1114092T1 (el) 2016-07-27
KR101540421B1 (ko) 2015-07-29
US8163923B2 (en) 2012-04-24
MX2009009843A (es) 2009-09-24
EP2125777A4 (en) 2011-06-22
CN101558055A (zh) 2009-10-14
PT2125777E (pt) 2013-07-04
AU2008226667B2 (en) 2013-05-23
ME02323B (me) 2016-06-20
SI2125777T1 (sl) 2013-08-30
US20080227812A1 (en) 2008-09-18
CA2681005C (en) 2017-06-06
CN101558055B (zh) 2014-03-12
HRP20130633T1 (en) 2013-08-31
JP2010521474A (ja) 2010-06-24
IL200854A (en) 2014-02-27
PL2125777T3 (pl) 2013-09-30
EP2125777B1 (en) 2013-04-10
CA2681005A1 (en) 2008-09-18
BRPI0808764B1 (pt) 2021-01-12
IL200854A0 (en) 2010-05-17
DK2125777T3 (da) 2013-06-24

Similar Documents

Publication Publication Date Title
BRPI0808764A2 (pt) compostos espiro-substituídos como inibidores de angiogênese
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
CY2017026I1 (el) Τετρακυκλικη ενωση
SMT201600008B (it) Composti di piridazinone
EP2519525A4 (en) SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS
BR112012000792A2 (pt) compostos heterocíclicos como inibidores de autotaxina
DK2427449T3 (da) Vinylindazolylforbindelser
BRPI1009800A2 (pt) compostos heterocíclicos como inibidores de autotaxina
BR112012006859A2 (pt) compostos
BRPI1016189A2 (pt) compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2
PT2506716T (pt) Novos compostos tricíclicos
BRPI1005525A2 (pt) compostos de azaazuleno
IL200934A0 (en) Spiro substituted compounds as angiogenesis inhibitors
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI1008774A2 (pt) espiroamida substituída
DOP2012000045A (es) Compuestos químicos
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI1013868A2 (pt) composto diaciletilenodiamina
BRPI0912475A2 (pt) compostos como inibidores de quinase
BR112012003868A2 (pt) Compostos orgânicos
UY33156A (es) Nuevos compuestos tienopirrol
EP2519519A4 (en) Substituted Naphthalenyl-pyrimidine compounds
PT2228158E (pt) Guia de brocas
EP2448583A4 (en) Substituted 4-hydroxypyrimidine-5-carboxamides

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: ADVENCHEN LABORATORIES, LLC (US)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.